Navigation Links
Biosensors Reports Financial Results for the Second Quarter and First Half of Fiscal Year 2014
Date:11/12/2013

and preliminary views, which are subject to change. It also excludes the potential impact from foreign exchange fluctuations, or any exceptional events and unforeseen circumstances that may occur.

"Although we have adjusted our full-year financial guidance, we remain confident about our company's growth prospects over the long run. In our core DES franchise, we expect key regions such as EMEA and APAC to continue to lead growth. In China, the industry slowdown is expected to persist in the near-term but we will focus on executing our sales strategy. Our partnership with Terumo in Japan to co-promote Nobori is on track. We will actively help Terumo improve Nobori sales going forward," said Dr. Wang. "Based on our recent approvals, we are working on multiple product launch plans to generate new revenues for the company. With the changing market conditions, management is implementing measures to enhance efficiency and improve profitability by restructuring its cost and operational compositions. We believe that the reorganization is necessary for us to better position ourselves to deliver our long-term goals."

Media/Investor Relations Contact

Wong Teck Yenn
Director, Investor Relations
Tel: (65) 6213 5777
Email: ir@biosensors.com

About Biosensors International Group, Ltd

Biosensors International Group, Ltd. develops, manufactures and markets innovative medical devices, aiming to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation. Founded in 1990, we were listed on the Mainboard of the Singapore Stock Exchange in 2005.

The Group currently operates through three business units ("BU"): cardiovascular BU, which includes the BioMatrix™ family of drug-eluting stents and the licensing of its proprietary drug-eluting stent technology; cardi
'/>"/>

SOURCE Biosensors International Group, Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2014
2. Biosensors Reports Financial Results for Fiscal Year 2013
3. Biosensors Completes Spectrum Dynamics Assets Acquisition
4. Biosensors to Acquire Assets of Spectrum Dynamics
5. Frost & Sullivan Acknowledges that PKCs Biosensors are Expected to Become the New Industry Standard in Pathogen Testing
6. Biosensors Reports Financial Results for the Third Quarter of Fiscal Year 2013
7. Biosensors Reports Strong Sales and Profitability in the First Quarter of Fiscal Year 2013
8. Mirati Therapeutics Reports Third Quarter 2013 Financial Results
9. BioSpecifics Technologies Corp. Reports Third Quarter 2013 Financial Results
10. Celsion Corporation Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Soligenix Reports Third Quarter 2013 Financial Results, and Highlights Recent Accomplishments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces ... is available in its catalogue: ... Markets to 2020 - Novel Therapeutic ... Newly Diagnosed and Recurrent GBM ... Glioblastoma Multiforme Therapeutics in ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... to 2020 - Broadened Diagnostic Criteria ... Market Growth despite Patent Expirations ... ADHD Therapeutics to 2020 - ...
(Date:8/28/2014)... , Aug. 28, 2014  Rx Safes, Inc., ... announced that it is waging a new war on ... national media campaign. More than 2,500 children ... time and these drugs are easily accessed from unsecured medicine ... drug dealers on the streets, Rx Safes will address ...
Breaking Medicine Technology:Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8Rx Safes, Inc. Announces New War On Drugs 2
(Date:8/28/2014)... these particular arguments against the policy, put forward by ... the first country in the world to introduce standardised ... Ireland, and the UK are currently considering similar legislation. ... policy would deter people from buying their tobacco from ... of cheap products sourced from Asia, and increase the ...
(Date:8/28/2014)... of women who are given information about the chance ... not fully understand the risks involved, according to research ... , today (Friday). , In a survey of around ... London (UCL) found that 64 per cent felt they ... chance that screening will pick up cancers that would ...
(Date:8/28/2014)... Millennium Treatment Group recently announced a new goal. ... Millennium Treatment Group is working to close it, providing more ... According to the National Survey on Drug Use and ... have benefited from treatment for drug and/or substance abuse, but ... that there is a large treatment gap in the United ...
(Date:8/28/2014)... Aug. 28, 2014 (HealthDay News) -- Arguments between parents ... study indicates. Parents in more than 200 families ... days. At the end of each day, mothers and ... relationship with their children. On days when parents ... with their children were also strained, according to the ...
(Date:8/28/2014)... York (PRWEB) August 28, 2014 ... bellwether trial of a transvaginal mesh lawsuit ( ... Inc., Bernstein Liebhard LLP reports. Court documents pending ... West Virginia indicate that the case was filed ... undergo two revision surgeries, allegedly due to vaginal ...
Breaking Medicine News(10 mins):Health News:Plain cigarette packs don't hurt small retailers or boost trade in illicit tobacco 2Health News:Some women still don't underststand 'overdiagnosis' risk in breast screening 2Health News:Millennium Treatment Group Works to Close Treatment Gap 2Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4
... Kids Dental July 1, LANSING, Mich., June 12 ... of Community Health (MDCH) today,announced an expansion of the ... Genesee and Saginaw counties, bringing the total,number of Michigan ... effect July 1, 2008., "We are extending needed ...
... anticancer drug sensitivity found in translation , The ... large problem. In some cases, such resistance is associated ... translation, which is central to the generation of proteins. ... McGill University, Montreal, have identified a drug that can ...
... June 12 MEDRAD, INC., has signed ... Solutions,a fully owned subsidiary of Siemens Medical ... care providers to inject Fluorodeoxyglucose,(FDG) for Positron ... innovative, new way. The partnership will leverage,MEDRAD,s ...
... molecular machinery is pointing toward new drugs and treatments ... era of personalized medicine, in which doctors aim to ... the right patient, also brings concerns about genetic privacy, ... , The American Association for the Advancement of Science ...
... Protection Act Will End Pre-Existing Condition,Limitations For Children ... Conditions, WASHINGTON, June 12 The National ... dedicated,to the mission of creating avenues of improved ... at the state and federal levels -- today,praised ...
... to track down source of salmonella-contaminated tomatoes , , ... ongoing outbreak of salmonella-contaminated tomatoes as a backdrop, ... and Drug Administration has failed to meet its ... supply. , Investigators for the Government Accountability Office ...
Cached Medicine News:Health News:Dental Services Expand to Serve More Than 280,000 Michigan Children 2Health News:JCI online early table of contents: June 12, 2008 2Health News:JCI online early table of contents: June 12, 2008 3Health News:JCI online early table of contents: June 12, 2008 4Health News:JCI online early table of contents: June 12, 2008 5Health News:JCI online early table of contents: June 12, 2008 6Health News:JCI online early table of contents: June 12, 2008 7Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 2Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 3Health News:AAAS hosts June 20 conference on personalized medicine 2Health News:National Patient Advocate Foundation Applauds Senators Lautenberg and Brown for Protecting Health Care Coverage for At-Risk Children 2Health News:National Patient Advocate Foundation Applauds Senators Lautenberg and Brown for Protecting Health Care Coverage for At-Risk Children 3Health News:Congressional Report Criticizes FDA for Food Safety 2Health News:Congressional Report Criticizes FDA for Food Safety 3Health News:Congressional Report Criticizes FDA for Food Safety 4Health News:Congressional Report Criticizes FDA for Food Safety 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: